Recent News

• 04.24.2025 - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
• 04.24.2025 - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
• 04.23.2025 - Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
• 04.02.2025 - Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities
• 03.17.2025 - Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

Recent Filings

• 04.15.2025 - DEFM14A Definitive proxy statement relating to merger or acquisition
• 04.04.2025 - 8-K Current report
• 04.04.2025 - 425 Prospectuses and communications, business combinations
• 04.04.2025 - 425 Prospectuses and communications, business combinations
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.18.2025 - 425 Prospectuses and communications, business combinations
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - 8-K Current report